Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2018-000004-42-GB
EUCTR2018-000004-42-GBActive, not recruitingPhase 1

TACE-3: A two-arm multi-stage (TAMS) seamless phase II/III randomised trial of nivolumab in combination with TACE/TAE for patients with intermediate stage HCC - TACE-3

The Clatterbridge Cancer Centre NHS Foundation Trust0 sites522 target enrollmentStarted: September 18, 2018Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
522
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Inclusion Criteria

  • •1.Histological diagnosis* of HCC and at least one uni-dimensional lesion measurable according to RECIST 1.1 criteria by CT-scan or MRI.
  • •2.Not a candidate for surgical resection or liver transplantation**
  • •3.Aged =16 years and estimated life expectancy >3 months
  • •4.ECOG performance status 0-1
  • •5.Adequate haematological function:
  • •Absolute neutrophil count =1.0x109/L
  • •Platelet count =60x109/L
  • •6.Bilirubin =50 µmol/L, AST,ALT and ALP =5 x ULN
  • •7.Adequate renal function; Creatinine = 1.5ULN (Using Cockcroft-Gault Formula)
  • •8.INR =1.6
  • •9.Child-Pugh A (score =6) (Appendix D)
  • •10.HAP score A, B or C (Appendix E)
  • •11.No contra-indications to T-cell checkpoint inhibitor therapy (use of immunosuppressive drugs including steroids at dose equivalent to prednisolone >10mg/day unless used as replacement therapy; organ transplantation; subjects with an active, known or suspected autoimmune disease. Subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, lichen planus or other conditions not expected to recur in the absence of an external trigger are permitted to enrol).
  • •12.Women of child-bearing potential should have a negative pregnancy test prior to study entry. Both men and women must be using an adequate contraception method, which must be continued for 5 months after completion of treatment for women and 7 months for men
  • •13.Written informed consent
  • •*All patients are required to under a MANDATORY biopsy prior to entry onto the study.
  • •**Criteria which establish ‘intermediate’ HCC
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range: 0
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 174
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 348

Exclusion Criteria

  • •1.Extrahepatic metastasis
  • •2.Prior embolisation, systemic or radiation therapy for HCC
  • •3.Any contraindications for hepatic embolisation procedures including portosystemic shunt, hepatofugal blood flow, known severe atheromatosis
  • •4.Investigational therapy or major surgery within 4 weeks of trial entry
  • •5.History of bleeding within the past 4 weeks
  • •6.Child-Pugh cirrhosis B or C (score =7)
  • •7.HAP score D
  • •8.Hepatic encephalopathy
  • •9.Ascites refractory to diuretic therapy
  • •10.Documented occlusion of the hepatic artery or main portal vein
  • •11.Hypersensitivity to intravenous contrast agents
  • •12.Active clinically serious infection > Grade 2 NCI-CTC
  • •13.Pregnant or lactating women
  • •14.Known history of HIV infection
  • •15.HBV chronic infection with HBV DNA = 500 IU/mL or without antiviral therapy; HBV patients with cirrhosis should be treated.
  • •16.History of second malignancy except those treated with curative intent more than three years previously without relapse and non-melanotic skin cancer or cervical carcinoma in situ
  • •17.Evidence of severe or uncontrolled systemic diseases, or laboratory finding that in the view of the Investigator makes it undesirable for the patient to participate in the trial
  • •18.Psychiatric or other disorder likely to impact on informed consent
  • •19.Patient is unable and/or unwilling to comply with treatment and study instructions
  • •20. Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected treatment-related pulmonary toxicity
  • •21. Evidence of uncontrolled, active infection, requiring parenteral anti-bacterial, anti-viral or antifungal therapy within 7 days prior to administration of study medication
  • •22. Positive test for latent TB or evidence of active TB
  • •23. Hypersensitivity to any of the active substances or excipients
  • •24. Patients who have received a live vaccine within 30 days prior to the first dose of trial treatment
  • •25. Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of the first dose of study drug administration
  • •26. Any uncontrolled inflammatory GI disease including Crohn’s Disease and ulcerative colitis
  • •27. Participants with an active, known or suspected autoimmune disease. Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enrol

Investigators

Similar Trials

Active, not recruiting
Phase 1
Mifepristone 50mg as a weekly ContraceptivePrevention of unwanted pregnancy
EUCTR2020-000866-41-Outside-EU/EEAWomen on Web International Foundation
Unknown
Phase 2
PanACEA-MAMS-TB-01Tuberculosis
PACTR201205000383208Prof. Karl Walter Jauch, Medical Director, Klinikum of the Universtiy of Munich372
Completed
Phase 2
A single arm phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab in combination with cetuximab in subjects with unresectable stage III or stage IV cutaneous squamous cell carcinoma (cSCC)cutaneous squamous cell carcinoma (cSCC), unresectable stage III or stage IVC44.9Malignant neoplasm of skin, unspecified
DRKS00017255Alcedis GmbH54
Active, not recruiting
Phase 1
A study to test activity and safety of treatment with avelumab in combination with cetuximab in patients suffering from non-operable squamous cell skin cancer.
EUCTR2018-001708-12-DEAlcedis GmbH52
Recruiting
Phase 1
A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 month to <18 years of age) with Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplantation (HSCT)Hematopoietic stem cell transplant-associated thrombotic microangiopathy(HSCT- TMA)MedDRA version: 20.0Level: SOCClassification code: 10005329Term: Blood and lymphatic system disorders Class: 3
CTIS2023-507850-33-00Alexion Pharmaceuticals Inc.40